Malaria.
Malaria is one of the most severe public health problems worldwide. Young children and pregnant women are most at risk.
Until recently, artemisinin-based combination therapies have provided effective treatment for early-diagnosed malaria. However, there is clear evidence of drug resistance and an urgent need for next-generation antimalarials to be curative while preventing transmission.
We have discovered that inhibiting the essential malaria protein kinase CLK3, particularly the Plasmodium falciparum protein kinase PfCLK3, can kill multiple parasite life stages and block transmission. Identifying this previously undiscovered druggable molecular pathway has led to the delivery of a small molecule clinical candidate for treating malaria.
With key development partners and our cutting-edge platform technology, we have a clear path to IND-ready clinical candidates to develop an antimalarial drug that is potentially prophylactic, curative and transmission-blocking.
Malarial candidate pipeline.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Innovative PEP-SMOL Platform technology.
Our innovative peptide-to-small molecule (PEP-SMOL) drug discovery platform addresses the key obstacles that have hindered pharmaceutical and biotechnology partners worldwide from targeting previously intractable therapeutically high-value protein receptors, known as G-Protein-Coupled-Receptors (GPCRs).
G-Protein-Coupled-Receptors
G-protein-coupled receptors (GPCRs) regulate most of our physiological processes and have great potential as therapeutic targets for a broad spectrum of diseases. However, many pharmacologically relevant GPCRs remain untapped and have, in many cases, been labelled as ‘hard to target’.
- ~34% of all marketed drugs (across all major therapeutic areas) are GPCR-targeted.
- Currently ~400 pharmacologically relevant GPCRs, with ~224 still to be explored.
- Our PEP-SMOL discovery platform aims to unlock these notoriously difficult-to-target receptors, opening a pipeline of innovative drug targets and high-value therapeutic applications.
- GPCR-based medicines can potentially treat areas of high unmet medical need, such as severe asthma, COPD and neurodegenerative and neuropsychiatric conditions.
Potential GPCR pipeline with Partner organisations (simple infographic – similar to malaria, perhaps with lung and brain icon to the left and discovery, lead, IND and clinical to the right.
Investors and Partners.
Together we can improve patients’ lives by unlocking the potential of high-value GPCR drug targets with our innovative peptide-to-small molecule drug discovery technology, PEP-SMOL. Discovering, developing, and commercialising a whole new world of next-generation treatments in areas of high unmet medical need.
Learn more about KELTIC Pharma.
We are happy to an answer questions about your Company, malaria, drug discovery platform technology and partnering opportunities.